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Summary.-Irrespective ofthe ethnicorigin ofthepatient, nasopharyngealcarcinoma
(NPC), appears to stimulate the production of IgA antibodies against VCA. These
antibodies are detected at high frequency and titres in sera from NPC patients but
only rarely from control subjects. A majority of relapse-free survivors tested 1-12
years after radiotherapy (RT) sustain a detectable level of IgA anti-VCA. Serum
titres of IgA anti-VCA remain relatively unchanged in individual NPC patients after
RT, regardless ofthe disease evolution. These antibodies were detected in serum from
one individual 9 months before NPC and the titre rose concomitantly with its clinical
onset.
Titres of IgA anti-VCA in multiple serum specimens fromindividual NPC patients,
and in sera from different NPC patients, do not correlate with titres of IgG anti-VCA
or with Serum IgA. It thus seems possible that the IgA anti-VCA in the sera of NPC
patients might be largely derived near NPC.
Apparently healthy individuals showing detectable IgA anti-VCA tend to aggregate
in families of NPC patients. The distribution of siblings of these families who have
the IgA anti-VCA reaction shows the binomial distribution expected for an autosomal
recessive trait, implying the involvement of an autosomal recessive gene in the IgA
anti-VCA response.
THE IgA antibody response to Epstein-
Barr virus-determined antigens seems to
be an outstanding feature of nasopharyn-
geal carcinoma (NPC). Serum IgA con-
centration was found to be significantly
higher in NPC patients than in control
subjects (Wara etal., 1975; Ho etal., 1976).
Henle and Henle (1976) reported that
NPC patients have high titres of IgA
antibody against viral capsid antigen
(VCA) (Henle and Henle, 1966) and early
antigens (EA) (Henle et al., 1970). These
reactivities are detected less frequently
and occur at lower titres in sera from
patients with Burkitt's lymphoma (BL)
and infectious mononucleosis (IM). Both
BL and IM, like NPC, are closely associa-
ted with EBV, such that all 3 groups of
patients have comparably high titres of
IgG antibodies against VCA (Henle and
Henle, 1976). Moreover, EBV is a ubiqui-
tous virus, such that all the healthy
Chinese subjects which served as one of
the control groups in our previous studies
had serum IgG antibodies against VCA,
but none had detectable IgA antibodies
(Ho et al., 1976). IgA antibody against
VCA was detected in the saliva from a
majority of NPC patients, but not from
healthy subjects or patients with other
cancers (Ho et al., 1977). Desgrange and
de The (1977) also reported similar
findings and, as suggested by these
authors, such antibodies might have inter-
fered with the isolation of EBV from the
throat washings of NPC patients. By
contrast, it was shown by Gerber et al.
(1972) that EBV is readily isolated from
the throat washings of IM patients.
It is apparent from the above that this
feature may have diagnostic applications,
and understanding of the mechanismsSERUM IgA ANTI-VCA IN NPC
underlying such response may yield infor-
mation on the state ofinfection with EBV
in NPC. In this paper, we report results
of our horizontal and longitudinal studies
with NPC patients before and after radio-
therapy (RT), and with family members
of these patients, who have a higher risk
of this disease than family members of
patients with other cancers (Ho, 1972).
The results have been analysed to evaluate
diagnostic applications of the IgA anti-
VCA test. They have also been analysed
in respect of IgG antibody response and
IgA serum concentration, in order to
understand further the nature of the
antigenic stimuli eliciting the IgA anti-
VCA response. There is a tendency for
individuals showing the IgA response to
aggregate in families of NPC patients.
The pattern of distribution of family
members having this response are, there-
fore, analysed to test whether genetic
factors are involved.
MATERIALS AND METHODS
Sera or plasma were obtained from Chinese
NPC patients before and after RT, and from
their apparently healthy family members.
The Tunisian and Caucasian NPC patients'
sera were kindly provided by Dr G. de The,
International Agency for Research on Cancer
(IARC), Lyon, France. Control sera were
obtained from healthy subjects (HS) con-
sisting of blood donors and traumatic-ward
patients due for discharge. Also included as
controls were sera from patients with other
cancers (OC). All specimens from Hong Kong
subjects were stored at -70°C and thawed
once immediately before use. Those from
IARC were packed in dry ice, despatched by
air and stored at -70°C upon arrival.
IgG and IgA antibodies against VCA were
determined by indirect immunofluorescent
technique using FITC-conjugated, heavy,-
chain-specific goat anti-human sera (Dako,
Denmark). Titres are expressed as the reci-
procal of the maximum serum dilution which
gives a positive immunofluorescence. IgA
concentration was determined by radial
immunodiffusion as previously described
(Ho, et 6l., 1977).
RESULTS
EBV serology of 1NIPC patients and controls
Titres of IgA and IgG anti-VCA were
determined in sera from 10 Chinese NPC
patients before RT and from 10 Caucasian
and 9 Tunisian NPC patients. The non-
Chinese NPC sera were kindly provided
by Dr G. de The. Among them, 1 Cauca-
sian and 2 Tunisian patients had IgA
anti-VCA titres <10, and they were
excluded from the calculation of values of
geometric mean titres (GMT) and 95%0
confidence limits for the respective groups
shown in Fig. 1. It is apparent that the
GMTs of these sero-reactivities for the
different ethnic groups of NPC patients
are similar. There is, however, a wider
scatter in IgA anti-VCA titres than in
titres of the IgG reactivity. Fig. 1 also
shows GMTs and 95%0 confidence limits
of serum IgG anti-VCA of 57 HS and 32
OC patients. All except 6 OC patients
among these controls had IgA anti-VCA
titres <10. The 6 OC patients showed
weak IgA anti-VCA reactivity at a serum
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FIGT. 1. Geometric mean titres (GAIP) of IgA
and IgG anti-VCA in NPC patients of
different ethnic origins, OC patients and I HS.
GMT ofIgG and IgAanti-VCA of 10 Chinle,se
(Chi), 9 Caucasian (Cau) an(d 7 Tunisian
(Ttun) NPC patients are shown (0), and the
correspon(ling 950% confidience levels as
(lotted lines. GMT of serum IgG anti-VCA
an(l 95% confideence limits were determine(d
in 57 HS an(l 32 OC patients with IgA ainti-
VCA titres <10. The IgG and IgA anti-VCA
titres of 2 Tunisian (A*) ancd 1 Caucasian
(A) NPC patients with IgA anti-VCA
titre <10 an(l 6 OC patients (0) with IgA
anti-VCA titre of 10 are shown. Arirows
denote diagniostic levels ofsertum anti-VCA.
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dilution of 1:10 and were considered to
have a titre of 10 for the purpose of
evaluating the diagnostic value of this
test. The IgA and IgG anti-VCA titres of
these 6 OC patients, and of the 2 Tunisian
and 1 Caucasian NPC patients who fell
outside the 9500 confidence limits deter-
mined for the respective groups, are
shown in Fig. 1.
The overall results indicate the possi-
bility of applying, concomitantly, IgG
and IgA anti-VCA reactivities in the
diagnosis of NPC. By setting values of
IgA and IgG anti-VCA titres of >10 and
>640 respectively as diagnostic, a detec-
tion rate for NPC of 26/29 and false-
positive rates of 2/32 for OC patients and
0/57 for HS may be anticipated.
The association between NPC and IgA
antibody against VCA was further invest-
igated in NPC patients before RT, in
their apparently healthy family members,
and in HS and OC patients. Sera or
plasma from these subjects were tested for
this reactivity at a dilution of :10
(Table I). A high frequency of detection
of IgA anti-VCA is clearly associated with
NPC. There is a higher frequency of
detection (X2 6X13, P < 0 02, DF 1)
TABLE I. Detection of IgA anti-VCA in
NPC Patients Before Radiotherapy, the
ApparentlyHealthySibsofNPCPatients,
Patients with Other Cancers (OC) and
Healthy Subjects (HS)
Subjects
NPC patients (Stages* I and II)
(Stages III an(l IV)
Total
Sibs of NPC patientst
OCT
HS§
Ntimber
(%) wvith
IgA anti-
VCA titres
> 10
34/38 (89%)
87/88 (990o)
121/126 (9'6"' )
28/133 (210o)
6/48 (13°/)
0/89 (°°/)
* Staging accordling to Ho (1970).
t From the families of 60 NPC patients.
1 33 patients wvith other headl ancd neck cancers
5 with Ca cervix, 4 Ca bladdler an(l 1 each with Cas
of uterine corpus, stomach, kidney, ovary, testis
and rectum.
§ 71 blood donors and 18 traumatic-ward patients
dlte for (lischarge.
among the NPC patients with regional
tumours (Stages III and IV) than among
those with local disease (Stages I and II).
The apparently healthy members of some
of the NPC patients' families showed a
frequency of detection of IgA anti-VCA
of 21.050°', which is significantly higher
than the values obtained for 1 S (X2
25-94, P < 0.01) but similar to that
observed in the OC patients (X2
= P69,
P > 0 10). Family members of NPC
patients are known to have a higher risk
ofthe disease than that offamily members
of OC patients (Ho, 1972). It seems
possible, therefore, that the detection of
IgA anti-VCA in these family members
might be related to an increased risk of
NPC, or, alternatively, they might be
already harbouring subclinical NPC.
Among them, we have now encountered
one individual who had an IgA anti-VCA
titre of 10 nine months before clinical
onset of NPC. Concomitantly, there was a
1]6-fold rise in her serum IgA anti-VCA
titre with clinical onset ofthe disease. Her
IgA anti-VCA titre then remained rela-
tively unchanged over a similar period
(Fig. 2).
IgA anti-VCA in strvivors after RT
Forty-seven NPC survivors with no
apparent clinical relapse for periods
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Fie. 2. IgA (*) andl IgG(*) anti-VCA titres
in sera from one sib of an NPC patient
before ancd after clinical onset of NPC.
NED, No evidence of dlisease; NPC,
clinical onset of the (lisease; RT, radio-
theirapy.
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between 1 and 12 years after RT were
tested for the presence of IgA anti-VCA
at a serum dilution of 1: 10. It is evident
from Table II that the majority of these
apparently relapse-free survivors sustain
serum IgA anti-VCA titres of >10. The
frequency of detection was higher for
NPC patients with regional tumours but
similar for the patients with local tumours
when compared with the survivors with
corresponding clinical stages before RT
(Table II).
a]
ti
NPC patients
(Stages I and II)
Survivors
(Stages* I and II)
NPC patients
(Stages III and IV)
Survivors
(Stages* III and IV)
protein concentration were also observed
after RT, which however did not appear
to be clearly related with the subsequent
clinical evolution.
b1zI
1281
321
81
21
W 512(
f Serum IgA anti- 'X 128(
Its and Relapse-free ; 321
after Radiotherapy 2
> <1'
.Tumber x2 P -
vith IgA Z 512C
nti-VCA <128C
itre > 10 < 32C
- 8C
34/38 o 2C
19/22 0*13 >0.70 ±
512C
87/88 - 128C
6-79 <0.01 3C
22/25 20
* Stage before RT.
Serum titres of IgA and IgG antibodies
against VCA, and IgA protein concentra-
tion, were determined in 8 NPC patients
before RT and at intervals over a period
of 30 months or more afterwards (Fig. 3).
Four of these patients had no clinical
evidence of relapse, whilst the other 4
had tumour recurrence during these
periods of observations. The IgA anti-
VCA titres of those patients with good
clinical evolution following RT tend to
remain unchanged or decrease slightly
from the pre-RT values. For one patient
with poor clinical evolution, whose serum
IgA anti-VCA titre was 10 before RT, it
remained at this level throughout. But
the other 3 patients showed a slight
decrease in IgA anti-VCA titres after RT
though the titres increased slightly again
at about the time ofclinical relapse. Slight
changes in IgG anti-VCA titres and IgA
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0 :
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FPJ. 3.-IgA (A) an(d IgG (0) anti-VCA
titres an(l IgA protein concentration (x) in multiple serum specimnens obtaine(d at
different times after RT' from indlivi(dtial
NPC patienits with no apl)arent symptoms
of the disease (NAD) or tulmouir recurrence?
(R) and/or metatasis (M). All p)atienits
Were given RI' at time z(ro an(I some we.ve
ag.flaini treated at times d(e1oted (14).
To test if IgA anti-VCA titres were
related with IgA protein concentration or
IgG anti-VCAtitres, we first compared the
patterns of changes in these values
observed in individual patients following
RT. The results showed no consistent
correlations (Table III). The results from a
comparison between patients also showed
no correlation between IgG anti-VCA
titres (r 0.03) or IgA protein concentra-
tion (r 4-3 x 10-5) and IgA anti-VGA
titres (Figs. 4 and 5).
TABLE II.-Detection o
VCA in NPC Patien
Survivors 1-12 Years
(RT)
Subjects
l, -.
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TABLE III. Association between Changes
in IgA anti-VCA Titres and IgG anti-
VCA Titres or IgA Concentrations in
Sernm from Individual NATPC Patients
No.
of ,-
log ]
serum titr(
specimens ant
5
9
7
4
8
7
8 -
6
12 -
Correlation coefficient
IgA (mg/
100 ml)
lgG anti-VCA and log
es and log IgA IgA anti-
;i-VCA titres VCA titres
0-2 0-72
0-62 0.09
0.59 0 73
0-58 -0-12
0-63 0-34
0-98 0-23
1-20 x 10-7 0-26
0-71 0-36
0357 0-71
5120
L1J2560 . . * - * it *
2560.
1280r - *
>6410 -.
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Fic1. 4.-Distribution of IgA and IgC anti-
VCA titres of serum specimens from NPC
patients before andl after RT.
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FiG. 5.-Distribution of JgA anti-VCA titres
and IgA protein concentration of serum
specimens from NPC patients before and
after RT.
Di)stribution of lNPC patients' siblings with
IgA anti-VCA titre >10
It was shown in Table I that individuals
with detectable IgA anti-VCA at a serum
or plasma dilution 1:10 tend to aggregate
in the families of NPC patients, but are
rarely found in the general population.
Among the NPC patients and their sibs,
there is a slight excess of males showing
this serum reactivity. It seemed possible
that the IgA antibody response might be
partly determined by an autosomal reces-
sive gene. To test this possibility further,
the distribution of siblings who showed a
detectable IgA anti-VCA reaction in
sibships of NPC patients was analysed
by the method of complete ascertainment
(Thompson and Thompson, 1966). This
TABLE IV.-The Observed and Expected Distribution of NPC Patients andSiblings with
IgA anti-VCA in Sibships of NPC Patients.
Total number of
Sibships Siblings
15 30
8 24
6 24
4 20
1
2
6
1 6
- *Expected No.
affecte(d
17-14
10-38
8-78
6-56
1-82
4-44
Observed number
JY
IgA anti-VCA
NPC 10
19 24
10 12
7 9
5 7
:3 5
2 5
x2t :=3'05 (P > 0-5) 8-66 (P > 0-1) Correlation coefficiernt -- 0-96 0-95
* Calculated by the method of complete ascertainment oIn assumption of autosomal Iecessive (see text).
t 5 degrees of free(dom.
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74/1238/8
72/583/5
74/585/4
76/110/1
74/495/4
73/1733/11
73/343/3
74/102/7
72/683/5
Size of
sibship
2
3
4
5
6
8
I
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method is based on a binomial distribution
of siblings showing an autosomal recessive
trait, and takes into account the truncated
selection of sibships for studies. Using
this method, the expected frequencies of
siblings with an autosomal recessive trait
were calculated for sibships of different
sizes. The observed frequencies of siblings
in sibships of different sizes who either
show adetectable IgA anti-VCAreactivity,
or who have NPC, agree with the values
expected if both characteristics were
determined by autosomal recessive genes
(Table IV).
DISCUSSION
NPC seems to constitute an important
antigenic stimulus for the production of
IgA antibodies against VCA. The depend-
ence of this serum activity on NPC is
further demonstrated, in one instance, by
the concomitant rise of IgA anti-VCA
titre with the clinical onset of NPC. The
same patient also had a high titre of
serum IgG anti-VCA 9 months before the
clinical onset of the disease. It would
appear from this one instance that occult
tumour may be a sufficient stimulus to
elicit a detectable IgA and an intense IgG
anti-VCA response. In contrast, however,
there appears to be a general lack of
correlation between IgA anti-VCA react-
ivity and apparent tumour load. Thus
there were only slight fluctuations in IgA
anti-VCA titres in NPC patients after RT.
These fluctuations did not seem to be
clearly related to disease evolution. The
frequency of detection of this serum
reactivity seems to be only slightly lower
in the relapse-free survivors after RT
than in NPC patients with similar disease
stages before RT. NPC patients with local
disease (Stages I or II) showed only a
slightly lower frequency of detection than
those with regional disease (Stages III or
IV) before RT. These results seem best
reconciled if one assumes that the IgA
anti-VCA response is very sensitive to
NPC, such that it is elicited whether the
disease is clinical or subclinical. None-
theless, it is apparent that the IgA anti-
VCA test cannot be used to evaluate the
evolution of NPC in individual patients.
It seems possible that IgA antibodies
against VCA may be produced locally in
the region of the tumour in the naso-
pharynx. This is compatible with the
presence of EBV genomes in NPC cells
(Klein et al., 1974) which may be activated
by treatment with halogenated nucleotides
to synthesize EBV antigens and viral
particles (Glaser et al., 1976; Trumper,
Epstein and Giovanella, 1976). Local
production of IgA anti-VCA may account
forthehighfrequency ofdetection ofthese
antibodies in saliva and throat washings
from NPC patients (Ho et al., 1977;
Desgranges and de The, 1977). Some of
these locally produced antibodies might
also be expected to reach the sys-
temic circulation. If this were to occur
extensively relative to the systemically
produced antibodies, a general lack of
correlation between serum IgA anti-VCA
titre and IgA protein concentration might
be anticipated, because the level of the
largely locally-derived antibodies in the
serum is not expected to be related to the
overall activity of the systemic IgA
immune system as reflected in the serum
IgA concentrations. Serum IgG anti-VCA
on the other hand, may be largely pro-
duced systemically and may thus reflect
the intensity of systemic stimulation by
VCA. The apparent lack of correlation
between titres of serum IgA and IgG
anti-VCA is thus compatible with different
sites of production of these antibodies.
The local production of IgA and IgG
antibodies has been further studied by us.
The results to be reported in the future
show that there is a frequent occurrence
of IgA plasma cells in NPC biopsy
specimens, while IgG plasma cells were
detected less frequently.
In an earlier study of concentrated
saliva from NPC patients, we reported
that the IgA antibodies in the majority
of these specimens lacked the secretory
piece, and it was speculated that this
might reflect their systemic origin (Ho
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et al., 1977). This is contrary to the
results of similar studies by Desgrange
and de The (1977) who found that, in
most instances, secretory pieces were
associated with the IgA antibodies in the
throat washings from NPC patients. This
discrepancy between the results of these
studies could be possibly due to dissocia-
tion of the secretory pieces from the IgA
molecules during concentration, or to a
difference in the antisera against the
secretory piece used in these studies (de
The, personal communication). We are
currently attempting to resolve this dis-
crepancy.
The observed frequency of detection of
IgA anti-VCA in the sibs of NPC falls
between those of NPC patients and
controls. It may be inferred from the one
instance described earlier of a sib of an
NPC patient who had detectable IgA
anti-VCA before clinical onset of NPC,
and from the persistence ofthis reactivity
in the relapse-free NPC survivors after
RT, that the apparently healthy sibs
withdetectableIgAanti-VCAmayharbour
subclinical NPC. On the other hand,
NPC patients' siblings with detectable
IgA anti-VCA showed the binomial distri-
bution pattern expected for the distribu-
tion of an autosomal recessive trait in
sibships of different sizes. This is consist-
ent with a possible genetic involvement in
the IgA antibody response to VCA
(Thompson and Thompson, 1966). Which-
ever the reason for the high frequency of
detection may be, it is important to carry
out a detailed study of EBV serology
among the sibs of NPC patients and this
is being pursued.
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